02/25/2026
In the randomized controlled Mammography Screening with Artificial Intelligence (MASAI) trial, recently published in the Lancet, researchers compared the use of adjunctive AI (Transpara, version 1.7.0., ScreenPoint Medical) for mammography triage to double reading by radiologists without AI in 105,915 women (approximate median age of 53).
The study authors found that that adjunctive AI facilitated a 12 percent reduction in the interval cancer rate and a 16 percent decrease in the rate of invasive interval breast cancers.
Among the women with detected interval cancers, the researchers noted that the adjunctive AI cohort had less Luminal B breast cancer (23 vs. 30 cases), triple-negative breast cancer (12 vs. 16) and HER2-positive, ER-positive breast cancer (5 vs. 7). Overall, there was a 27 percent reduction in the number of invasive cases involving non-Luminal A molecular subtypes with the use of adjunctive AI in screening (43 vs. 59 cases).
“The interval cancer rate is an important indicator of screening efficacy, and although this study was not powered to show superiority, these results suggest a potential clinical benefit of earlier detection of clinically relevant breast cancer, which might enable less aggressive treatment and improved prognosis,”noted lead study author Jessie Gommers, MSc, who is affiliated with the Department of Medical Imaging at Radboud University Medical Center in Nijmegen, Netherlands, and colleagues.
The researchers also pointed out higher sensitivity rates with adjunctive AI regardless of age or breast density category. For women with extremely dense breasts, adjunctive AI facilitated an 11.1 percent increase in sensitivity (71.1 percent vs. 60 percent). In addition to the higher overall sensitivity rate with adjunctive AI (80.5 percent vs. 73.8 percent, the study authors noted equivalent specificity (98.5 percent).
Get Most Advanced Diagnosis: ☎️ 954-905-7217
Choose Diversity MRI: www.diversitymri.com
